$VINC
Vincerx Pharma, Inc.

2020 Q3 Form 10-K Financial Statement

#000156459020044380 Filed on September 23, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2020
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.600M
YoY Change
% of Gross Profit
Research & Development $2.116M
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $440.4K $130.0K $10.71M
YoY Change 440286.0%
Operating Profit -$440.4K -$10.71M
YoY Change 440286.0%
Interest Expense $10.00K $30.00K $8.000K
YoY Change -84.0%
% of Operating Profit
Other Income/Expense, Net -$8.000K
YoY Change
Pretax Income -$430.0K -$110.0K -$16.62M
YoY Change
Income Tax $0.00 $812.00
% Of Pretax Income
Net Earnings -$434.3K -$110.0K -$10.72M
YoY Change 434204.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$262.2K -$67.07K -$3.166M
COMMON SHARES
Basic Shares Outstanding 8.205M 8.205M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2020 Q2 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $560.0K $680.0K $61.79M
YoY Change 205866.67%
Cash & Equivalents $562.8K $684.7K $61.79M
Short-Term Investments
Other Short-Term Assets $70.00K $110.0K $1.310M
YoY Change 1090.91%
Inventory
Prepaid Expenses $106.3K
Receivables
Other Receivables
Total Short-Term Assets $640.0K $791.0K $63.11M
YoY Change 3064.16% 210266.67%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $65.70M $65.69M
YoY Change
Other Assets $80.00K
YoY Change
Total Long-Term Assets $65.69M $65.69M $80.00K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $640.0K $791.0K $63.11M
Total Long-Term Assets $65.69M $65.69M $80.00K
Total Assets $66.33M $66.48M $63.19M
YoY Change 265831.91% 210533.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $400.0K $120.0K $490.0K
YoY Change
Accrued Expenses $115.5K
YoY Change 7862.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $10.00K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $400.0K $116.3K $37.81M
YoY Change 7918.21%
LONG-TERM LIABILITIES
Long-Term Debt $1.000M $1.000M $0.00
YoY Change
Other Long-Term Liabilities $2.300M $2.300M
YoY Change
Total Long-Term Liabilities $3.300M $3.300M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $400.0K $116.3K $37.81M
Total Long-Term Liabilities $3.300M $3.300M $0.00
Total Liabilities $3.700M $3.414M $37.81M
YoY Change 235319.52%
SHAREHOLDERS EQUITY
Retained Earnings -$555.3K -$121.0K
YoY Change 8244.28%
Common Stock $244.00 $240.00
YoY Change 66.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.000M $5.000M $25.38M
YoY Change
Total Liabilities & Shareholders Equity $66.33M $66.48M $63.19M
YoY Change 265831.91% 210533.33%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2020
OPERATING ACTIVITIES
Net Income -$434.3K -$110.0K -$10.72M
YoY Change 434204.0%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$121.9K -$70.00K -$2.279M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 -$65.64M
YoY Change 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.000K
YoY Change -96.67%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 64.07M
YoY Change 213470.0%
NET CHANGE
Cash From Operating Activities -121.9K -70.00K -2.279M
Cash From Investing Activities 0.000 -65.64M
Cash From Financing Activities 0.000 64.07M
Net Change In Cash -121.9K -70.00K 61.79M
YoY Change 205873.33%
FREE CASH FLOW
Cash From Operating Activities -$121.9K -$70.00K -$2.279M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q2 us-gaap Assets
Assets
66482977
CY2020Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
812
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
116264
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1450
CY2020Q2 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
1000000
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020Q3 dei Entity Public Float
EntityPublicFloat
0
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8204709
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Shell Company
EntityShellCompany
true
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 dei Entity File Number
EntityFileNumber
001-39244
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-3197402
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
250 W. 55th St., #3401
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
CY2020 dei City Area Code
CityAreaCode
646
CY2020 dei Local Phone Number
LocalPhoneNumber
889-1200
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q2 us-gaap Cash
Cash
684708
CY2019Q2 us-gaap Cash
Cash
25000
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
106333
CY2020Q2 us-gaap Assets Current
AssetsCurrent
791041
CY2019Q2 us-gaap Assets Current
AssetsCurrent
25000
CY2020Q2 us-gaap Long Term Investments
LongTermInvestments
65691936
CY2019Q2 us-gaap Assets
Assets
25000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
115452
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1450
CY2020Q2 lsacu Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
2297319
CY2020Q2 us-gaap Liabilities
Liabilities
3413583
CY2019Q2 us-gaap Liabilities
Liabilities
1450
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
58069390
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
240
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
144
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5120756
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24856
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-120992
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1450
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
5000004
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
23550
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66482977
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25000
CY2020Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
5806939
CY2019Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
10.00
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
us-gaap Net Income Loss
NetIncomeLoss
-1450
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
225000
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2397770
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1437500
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2397770
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1437500
CY2020 us-gaap Operating Expenses
OperatingExpenses
172996
us-gaap Operating Expenses
OperatingExpenses
1450
us-gaap Operating Income Loss
OperatingIncomeLoss
-1450
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
812
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-119542
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
lsacu Issuance Of Common Stock To Sponsor Value
IssuanceOfCommonStockToSponsorValue
25000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
61880386
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1285000
CY2020 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
58069390
CY2020 us-gaap Profit Loss
ProfitLoss
-119542
us-gaap Profit Loss
ProfitLoss
-1450
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
106333
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
114002
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1450
CY2020 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
812
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-165327
CY2020 lsacu Investment Of Cash In Trust Account
InvestmentOfCashInTrustAccount
65637670
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-65637670
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25000
CY2020 lsacu Proceeds From Sale Of Units Net Of Underwriting Discounts Paid
ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountsPaid
64574917
CY2020 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
1285000
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
175000
CY2020 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
175000
CY2020 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1000000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
397212
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
66462705
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
659708
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
25000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
684708
CY2020 lsacu Noncash Or Part Noncash Initial Classification Of Common Stock Subject To Possible Redemption
NoncashOrPartNoncashInitialClassificationOfCommonStockSubjectToPossibleRedemption
58188310
CY2020 lsacu Noncash Or Part Noncash Change In Value Of Common Stock Subject To Possible Redemption
NoncashOrPartNoncashChangeInValueOfCommonStockSubjectToPossibleRedemption
-118920
CY2020 lsacu Noncash Or Part Noncash Deferred Underwriting Fee Payable
NoncashOrPartNoncashDeferredUnderwritingFeePayable
2297319
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. At June 30, 2020 and 2019, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
CY2020 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-12-19
CY2020Q1 us-gaap Common Stock Held In Trust
CommonStockHeldInTrust
60000000
CY2020Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.00
CY2020Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3757284
CY2020 lsacu Payment Of Underwriter Fees
PaymentOfUnderwriterFees
1062753
CY2020Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2297319
CY2020 lsacu Payment Of Other Offering Costs
PaymentOfOtherOfferingCosts
397212
CY2020Q2 us-gaap Business Acquisition Share Price
BusinessAcquisitionSharePrice
10.00
CY2020Q2 lsacu Net Tangible Asset After Business Combination
NetTangibleAssetAfterBusinessCombination
5000001
CY2020 us-gaap Business Acquisition Effective Date Of Acquisition1
BusinessAcquisitionEffectiveDateOfAcquisition1
2022-03-10
CY2020 lsacu Percentage Of Outstanding Public Shares Redeemed
PercentageOfOutstandingPublicSharesRedeemed
1.00
CY2020Q2 lsacu Redemption Price Per Share
RedemptionPricePerShare
10.00
CY2020Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2019Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2019Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
225000
CY2020 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
9133767
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
54266
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
51212
CY2020 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
3054
CY2020Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2020Q1 lsacu Number Of Demands Of Registration Rights
NumberOfDemandsOfRegistrationRights
2
CY2020Q1 lsacu Number Of Demand Registration Rights At Expense
NumberOfDemandRegistrationRightsAtExpense
1
CY2020Q1 lsacu Demand Registration Rights Exercise Period
DemandRegistrationRightsExercisePeriod
P5Y
CY2020Q1 lsacu Piggy Back Registration Rights Exercise Period
PiggyBackRegistrationRightsExercisePeriod
P7Y
CY2020Q1 lsacu Underwriter Cash Discount Per Share
UnderwriterCashDiscountPerShare
0.20
CY2020Q1 lsacu Aggregate Cash Discount For Underwriter
AggregateCashDiscountForUnderwriter
1312753
CY2020Q1 lsacu Underwriter Deferred Fee Per Unit
UnderwriterDeferredFeePerUnit
0.35
CY2020Q1 lsacu Underwriter Deferred Fee
UnderwriterDeferredFee
2297319
CY2020 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of the Company’s common stock are entitled to one vote for each share.
CY2020Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
5806939
CY2019Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2020 lsacu Warrant Expiration Term
WarrantExpirationTerm
P5Y
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2020Q2 lsacu Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
25745
CY2020Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
25745
CY2020Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
25745
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
812
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-25745
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
25745
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.217
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.007

Files In Submission

Name View Source Status
lsacu-20200630.xsd Edgar Link pending
0001564590-20-044380-index-headers.html Edgar Link pending
0001564590-20-044380-index.html Edgar Link pending
0001564590-20-044380.txt Edgar Link pending
0001564590-20-044380-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
lsacu-10k_20200630.htm Edgar Link pending
lsacu-20200630.xml Edgar Link completed
lsacu-20200630_cal.xml Edgar Link unprocessable
lsacu-20200630_def.xml Edgar Link unprocessable
lsacu-20200630_lab.xml Edgar Link unprocessable
lsacu-20200630_pre.xml Edgar Link unprocessable
lsacu-ex311_8.htm Edgar Link pending
lsacu-ex312_7.htm Edgar Link pending
lsacu-ex32_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending